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Purpose: This study aimed to elucidate whether stone removal by extracorporeal 
shock wave lithotripsy (ESWL) is associated with delayed chronic kidney disease 
(CKD) progression. Materials and Methods: We conducted a retrospective anal-
ysis of 131 nephrolithiasis patients with stage 3 and 4 CKD. We collected baseline 
clinical and laboratory data, kidney stone characteristics, and history of receiving 
ESWL. We classified study patients into two groups according to whether they un-
derwent ESWL or not (Non-ESWL group vs. ESWL group). We initially compared 
annual estimated glomerular filtration rate (eGFR) changes of Non-ESWL group 
with those of ESWL group before undergoing ESWL. In the next step, we sought 
to compare annual eGFR changes in the same patients before and after ESWL. Fi-
nally, we compared annual eGFR changes between success and failure groups 
among patients undergoing ESWL. Results: The mean age of the patients was 62 
years and 72.5% were male. The mean observation period was 3.2 years. Non-ES-
WL group and ESWL group before undergoing ESWL showed similar annual 
eGFR changes (-1.75±6.5 vs. -1.63±7.2 mL/min/1.73 m2/year, p=0.425). Howev-
er, eGFR declined slower after undergoing ESWL than before ESWL (annual 
eGFR changes, -0.29±6.1 vs. -1.63±7.2 mL/min/1.73 m2/year, p<0.05). In addi-
tion, among patients in ESWL group, eGFR declined faster in the failure group 
than in the success group (annual eGFR change, -1.01±4.7 vs. -0.05±5.2 mL/
min/1.73 m2/year, p<0.05). Conclusion: Our results suggest that stone removal by 
ESWL is associated with delayed deterioration of renal function in CKD patients 
with nephrolithiasis.
Key Words:    Nephrolithiasis, chronic kidney disease, extracorporeal shock wave 
lithotripsy (ESWL), glomerular filtration rate (GFR)
INTRODUCTION
         
Kidney stone or nephrolithiasis commonly affects 1.7 to 14.8% of the general pop-
ulation, and both prevalence and incidence have increased globally across age, 
gender, and race, resulting in increased morbidity.1 In cases of kidney stones aris-ESWL in CKD Patients with Nephrolithiasis
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twice before the diagnosis of nephrolithiasis to confirm that 
patients had CKD. It also had to be followed at least once 
every 6 months after the diagnosis to include patients in this 
study. Fifteen patients were excluded due to inadequate in-
formation on eGFR. Patients who had transplanted kidney 
or solitary kidney were excluded (n=8). Patients with stag-
horn stone were also excluded (n=3) because those stones 
resulted in complete obstruction of renal pelvis. Patients 
who had been followed for less than 12 months were ex-
cluded (n=10). We also excluded patients with polycystic 
kidney disease (n=1) and/or genitourinary system cancer 
(n=1). Consequently, we identified 131 patients who met 
the study criteria and these patients were included in the fi-
nal analyses (Fig. 1).
   
Data collection
Using a retrospective review of patient medical records, the 
following demographic and clinical data were collected: 
age at the time of diagnosis; gender; height; weight; comor-
bidities including diabetes mellitus, hypertension, and car-
diovascular disease; stone characteristics including location 
(unilateral vs. bilateral), number (solitary vs. multiple), and 
diameter; and history of receiving ESWL. We also collect-
ed laboratory parameters including hemoglobin, calcium, 
phosphorus, blood urea nitrogen, serum creatinine, total pro-
tein, albumin, and aspartate/alanine aminotransferase. Pro-
teinuria was defined when random urine protein-to-creati-
nine ratio was greater than 0.2 mg/mg.
We classified study patients into two groups according to 
ing from rare hereditary disorders or staghorn stones result-
ing from chronic urinary tract infection with urease-con-
taining bacteria, kidney stones have evidently been reported 
to cause significant chronic renal damage and sometimes 
lead to end stage renal disease (ESRD).2-5 However, the 
United States Renal Data System 2010 Annual Data Report 
showed that only 2.4% of all ESRD were caused by these 
kinds of kidney stones.6 
Although the impact of kidney stones on the renal function 
has not yet been clearly elucidated, recent studies showed 
that kidney stones might be associated with increased risk of 
development of chronic kidney disease (CKD).7-10 However, 
in patients who already have CKD, little is known as for 
whether the presence of kidney stones influences the pro-
gression of CKD and whether removal of kidney stones 
could modify the course of CKD progression. Moreover, 
long-term effect of extracorporeal shock wave lithotripsy 
(ESWL) on the renal function deterioration in CKD popu-
lation has not been studied to date. Therefore, we undertook 
this study to elucidate whether stone removal by ESWL 
would be associated with delayed CKD progression in CKD 
patients with kidney stones that are not associated with uri-
nary tract obstruction.
MATERIALS AND METHODS
　　　
Study setting and patient selection
This is a retrospective single center study approved by insti-
tutional review board. The study subjects initially consisted 
of patients with nephrolithiasis, who were identified by using 
International Classification of Diseases, Tenth Revision 
(ICD-10) codes: N20.0 (calculus of kidney), N20.9 (urinary 
calculus, unspecified), and N23 (unspecified renal colic). A 
comprehensive review of medical records was then conduct-
ed to confirm, or reject potential cases of nephrolithiasis 
without hydronephrosis. Between January 2002 and Decem-
ber 2009, a total of 2022 patients were confirmed by ultraso-
nography and/or computed tomography to have kidney 
stones without hydronephrosis. Of these patients, 169 were 
eligible for the study because they had an estimated glomeru-
lar filtration rate (eGFR) between 15 and 60 mL/min/1.73 m2 
before the initial diagnosis of nephrolithiasis, which were cal-
culated using the 4-variable Modification of Diet in Renal 
Disease (MDRD) Study equation: eGFR=186×[serum creat-
inine (mg/dL)]-1.154×[age]-0.203×[0.742 if female]×[1.210 if 
black].11 eGFR had to be documented consecutively at least 
Fig. 1. Flow diagram indicating patient recruitment and exclusion. CKD, 
chronic kidney disease; eGFR, estimated glomerular filtration rate; CT, com-
puted tomography; US, ultrasonography.
Assessed for eligibility:
-Kidney stones on CT or US between 2002 and 2009
-Without hydronephrosis
(n=2022)
Excluded (n=1853)
-CKD stage 1 and 2 (n=1822)
-CKD stage 5 (n=31)
Enrolled patients (n=131)
Excluded (n=38)
-Inadequate information on eGFR 
  change (n=15)
-Solitary kidney or transplanted 
  kidney (n=8)
-Staghorn stone (n=3)
-Followed for less than 1 year (n=10)
-Polycystic kidney (n=1)
-Genitourinary system cancer (n=1)Dong Eun Yoo, et al.
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compared with the use of Mann-Whitney U test for continu-
ous variables and Fisher’s exact test for categorical variables.
A p-value of less than 0.05 was considered to indicate 
statistical significance. All calculations were computed with 
the aid of PASW Statistics software (version 18).
 
RESULTS
 
Baseline characteristics of study patients
The mean age of the study sample was 62 years (range, 28-
82 years), and 72.5% were male. Of the 131 patients, 123 
(93.9%) had CKD stage 3 at baseline. Primary renal diseas-
es were diabetic nephropathy (40.5%), hypertensive ne-
phropathy (32.1%), chronic glomerulonephritis (11.5%), 
and CKD from other causes (16.1%). Average systolic and 
diastolic blood pressures at baseline were 133.9 and 77.5 
mm Hg, respectively. Mean diameter of kidney stones was 
2.1±0.6 cm, and 48.1% of patients had bilateral kidney 
stones. Among all patients, 34 (26.0%) patients underwent 
ESWL for stone removal and received 3425±560 shocks 
per stone with mean voltage of 5.7±1.3 kV over 2.2±1.4 
sessions per stone.
Comparison of clinical and laboratory findings between 
Non-ESWL and pre-ESWL groups
Table 1 shows clinical and laboratory findings between the 
Non-ESWL and Pre-ESWL groups. No differences in age, 
gender, body mass index (BMI), systolic and diastolic pres-
sure, prevalence of comorbidities including hypertension, 
diabetes and CVD, stone characteristics, and baseline eGFR 
were found between the two groups. In addition, laboratory 
findings such as hemoglobin, calcium, phosphate, uric acid, 
cholesterol, and proteinuria were not different between the 
groups. Moreover, Non-ESWL group and pre-ESWL group 
showed similar annual eGFR changes (-1.75±6.5 vs. -1.63± 
7.2 mL/min/1.73 m2/year, p=0.425). However, follow-up 
duration of Non-ESWL group was longer than that of pre-
ESWL group (3.0±1.2 vs. 1.7±1.1 years, p=0.047). Howev-
er, total follow-up duration including both before and after 
ESWL was comparable to that of Non-ESWL group (3.0± 
1.2 vs. 3.9±1.2 years, p=0.152).
Comparison of annual eGFR changes before and after 
ESWL among patients undergoing ESWL, and 
complications after ESWL
Patients who underwent ESWL were followed for 1.7 years 
whether they underwent ESWL or not (Non-ESWL group 
vs. ESWL group). Annual eGFR change was calculated us-
ing all available data during follow-up period for Non-ES-
WL patients. In contrast, pre-ESWL and post-ESWL annu-
al eGFR changes were respectively estimated for study 
patients who underwent ESWL. We used eGFR data up to 
2 years before undergoing ESWL and additional consecu-
tive eGFR data after ESWL for these patients. Annual eGFR 
change was estimated by using a linear regression model of 
time on eGFR in each patient, and it was defined as coeffi-
cient of regression of this regression model.
In terms of data related to ESWL, following variables 
were collected: sessions per stone, voltage, number of 
shocks per stone, and stone clearance rate at 3 months after 
ESWL. Success of stone clearance was defined as achiev-
ing stone-free status or having clinically insignificant resid-
ual fragments. On the contrary, failure of stone clearance 
was defined as showing no response or having significant 
residual fragments.
We initially compared annual eGFR changes of Non-ES-
WL group to those of ESWL group before undergoing ESWL 
(pre-ESWL). In the next step, we sought to compare annual 
eGFR changes during pre-ESWL period with those after 
undergoing ESWL (post-ESWL). Finally, we analyzed dif-
ferences between success and failure groups among pa-
tients undergoing ESWL.
ESWL technique
ESWL had been performed with EDAP LT-02 (Technomed, 
Lyon, France) until April 2005, and it was replaced by EDAP 
Sonolith Praktis since May 2005. ESWL therapy usually 
started at a low voltage of 5 kV until the patient became ac-
customed to the shocks, and the voltage was then gradually 
increased to a maximum of 9 kV. The average number of 
shocks per session was 2000-4000.
 
Statistics
Continuous data are expressed as mean±standard deviation. 
Categorical data are presented as absolute values and percent-
ages. Clinical characteristics of the Non-ESWL and pre-ES-
WL groups were compared with the use of Student t-test for 
continuous variables and the chi-square test or Fisher’s exact 
test for categorical variables. Annual eGFR changes before 
and after ESWL in patients who underwent ESWL were 
compared using paired t-test. Owing to paucity of number of 
patients undergoing ESWL, characteristics between success 
and failure groups among patients receiving ESWL were ESWL in CKD Patients with Nephrolithiasis
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before ESWL and for 2.3 years after ESWL. To clarify 
whether ESWL affected the renal function decline rate in 
CKD patients, annual eGFR changes before and after ESWL 
were compared. The result showed that eGFR after ESWL 
declined slower than eGFR before undergoing ESWL (annu-
al eGFR changes, -0.29±6.1 vs. -1.63±7.2 mL/min/1.73 m2/
year, p<0.05), as depicted in Fig. 2. 
In terms of complications that occurred after ESWL, sub-
capsular hematoma occurred in 2.9% of patients, which was 
clinically insignificant. Although urinary tract infections also 
occurred in 8.7% of patients after ESWL, all cases were suc-
cessfully cured with antibiotics therapy. Clinically significant 
urinary tract obstruction from stone fragments after ESWL 
occurred in 5.8% of patients, and ureteroscopic procedures 
Table 1. Comparison of Baseline Characteristics between Non-ESWL and Pre-ESWL Groups
Total
n=131
Non-ESWL
n=97
ESWL (pre-ESWL)
n=34 p value
Age, yrs (SD)    62.3±11.3     63.3±10.0     61.2±14.3 0.325
Male gender (%)   95 (72.5) 69 (71.1) 26 (76.5) 0.557
BMI (kg/m
2)    19.7±10.0     19.6±10.5   20.2±8.4 0.696
Systolic blood pressure (mm Hg)  133.9±10.2 132.7±8.5 134.3±9.5 0.520
Diastolic blood pressure (mm Hg)  77.5±8.1   78.2±8.1   77.1±7.3 0.453
Comorbidities (%)
    Hypertension   93 (71.0) 74 (76.3) 19 (55.9) 0.093
    Diabetes   59 (45.0) 40 (41.2) 19 (55.9) 0.865
    CVD   34 (26.0) 23 (23.7) 11 (32.4) 0.415
Stone characteristics (%)
    Bilateral   63 (48.1) 50 (51.5) 13 (38.2) 0.377
    Multiple   85 (64.9) 63 (64.9) 22 (64.7) 0.881
    Stone diameter (cm)    2.1±0.6     2.1±0.6     2.1±0.5 0.315
Baseline eGFR (mL/min/1.73 m
2) (%)  49.4±9.0   49.2±8.8   50.0±9.8 0.959
    CKD stage 3 123 (93.9) 91 (93.8) 32 (94.1)
    CKD stage 4   8 (6.1) 6 (6.2) 2 (5.9)
Hemoglobin, g/dL  13.5±2.0   13.2±1.9   14.1±2.2 0.252
Calcium, mg/dL    9.5±0.7     9.5±0.7     9.5±0.5 0.630
Phosphate, mg/dL    3.6±0.6     3.6±0.6     3.5±0.6 0.532
Glucose, mg/dL  116.1±40.6   113.4±36.7   123.9±50.2 0.490
Uric acid, mg/dL    6.5±1.8     6.7±1.8     5.9±1.7 0.133
Cholesterol, mg/dL  177.9±35.9   176.3±35.6   182.5±37.5 0.515
Albumin, g/dL    4.5±0.4     4.5±0.4     4.5±0.3 0.998
Proteinuria, n (%)   19 (14.5) 9 (9.3) 10 (29.4) 0.101
Mean annual change of eGFR 
  (mL/min/1.73 m
2/yr) -1.68±6.1 -1.75±6.5  -1.63±7.2 0.425
Follow-up duration, yrs    2.7±1.2     3.0±1.2     1.7±1.1 0.047
ESWL, extracorporeal shock wave lithotripsy; BMI, Body Mass Index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; CKD, chronic 
kidney disease; SD, standard deviation.
Data are presented as mean±SD or n (%). 
Fig. 2. Comparison of annual eGFR decline between ESWL and Non-ESWL 
group. ESWL, extracorporeal shock wave lithotripsy; eGFR, estimated glo-
merular filtration rate.
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success and failure groups (Table 2). There were no differ-
ences in age, gender, BMI, blood pressure, prevalence of 
comorbidities, and stone characteristics between the 
groups. In addition, laboratory findings including hemoglo-
bin, calcium phosphate, cholesterol, and proteinuria were 
comparable between the groups. Although baseline eGFR 
at the time of ESWL were slightly greater in the success 
group than in the failure group, the difference was not sta-
tistically significant. However, eGFR declined faster in the 
failure group than in the success group (annual eGFR 
were needed to decompress the obstruction for these patients.  
   
Comparision of characteristics between success and 
failure groups among patients undergoing ESWL
Among patients undergoing ESWL, the success rate of 
stone clearance at 3 months after ESWL was 73.5%. To 
elucidate whether the stone clearance after ESWL is associ-
ated with annual eGFR changes after ESWL, we compared 
characteristics of patients between success and failure 
groups. we compared characteristics of patients between 
Table 2. Comparison of Characteristics between Success and Failure Groups among Patients Receiving ESWL
Total
n=34
Success
n=25
Failure
n=9 p value
Age, yrs (SD)     59.2±14.3     61.9±11.0    55.6±18.7 0.104
Male gender (%) 26 (76.5) 22 (88.0) 4 (44.4) 0.144
BMI (kg/m
2)   21.2±8.4   21.0±9.9   21.7±2.9 0.206
Systolic blood pressure (mm Hg) 134.3±9.5 134.8±8.4 133.9±9.0 0.354
Diastolic blood pressure (mm Hg)   77.1±7.3   77.4±7.2   77.0±8.1 0.421
Comorbidities (%)
    Hypertension 19 (55.9) 13 (52.0) 6 (66.7) 0.314
    Diabetes 19 (55.9) 13 (52.0) 6 (66.7) 0.326
    CVD 11 (32.4) 10 (40.0) 1 (11.1) 0.615
Stone characteristics (%)
    Bilateral 13 (38.2)   9 (36.0) 4 (44.4) 0.959
    Multiple 22 (64.7) 17 (68.0) 5 (55.6) 0.959
    Stone diameter (cm)     2.1±0.5     2.1±0.7     2.0±0.4 0.542
eGFR at ESWL (mL/min/1.73 m
2)  (%)   50.0±9.8   52.9±6.6     42.4±13.3 0.068
    CKD stage 3 32 (94.1) 24 (96.0) 8 (88.9)
    CKD stage 4 2 (5.9) 1 (4.0) 1 (11.1)
Hemoglobin, g/dL   14.1±2.2   14.3±2.1   13.4±2.7 0.395
Calcium, mg/dL     9.5±0.5     9.6±0.6     9.4±0.3 0.915
Phosphate, mg/dL     3.5±0.6     3.5±0.5     3.4±0.7 0.399
Glucose, mg/dL   123.9±50.2   118.3±39.2   138.4±75.8 0.693
Uric acid, mg/dL     5.9±1.7     5.9±1.4    6.0±2.3 0.792
Cholesterol, mg/dL   182.5±37.5   178.6±43.0  192.0±19.0 0.916
Albumin, g/dL     4.5±0.3     4.6±0.2     4.4±0.3 0.098
Proteinuria, n (%) 10 (29.4)   6 (24.0) 4 (44.4) 0.533
ESWL settings
    Sessions per stone     2.2±1.4     2.2±1.2     2.1±1.4
    Voltage (kV)     5.7±1.3     5.7±1.2     5.7±1.2
    Numbers of shocks per stone  3425±560   3430±552   3421±530
Mean annual change of eGFR 
  (mL/min/1.73 m
2/yr) -0.29±6.1  -0.05±5.2  -1.01±4.7 0.043
Follow-up duration, yrs    2.3±1.1     2.3±0.9     2.2±1.4 0.408
ESWL, extracorporeal shock wave lithotripsy; BMI, Body Mass Index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; CKD, chronic 
kidney disease; SD, standard deviation. 
Data are presented as mean±SD or n (%). ESWL in CKD Patients with Nephrolithiasis
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nied by focal sites of parenchymal and subcapsular hemor-
rhage.14 Tubules also show features similar to the tears seen 
in the vessel walls. In addition, ESWL-treated kidneys show 
a short-term reduction in renal plasma flow.15 Moreover, ES-
WL-induced trauma triggers the infiltration of inflammatory 
cells at the site of the lesion.16 Taken together, ESWL trauma 
is regarded to cause scar formation and loss of functional 
renal mass.14 In contrast, however, other recent studies re-
ported that renal function impairment associated with ESWL 
is largely resolved within 1 to 3 months and ESWL per se 
has no significant long-term effects on renal function.17,18 
However, the patients included in these studies had normal 
renal function, and the effect of ESWL in CKD patients was 
not addressed. Interestingly, our present study showed that 
eGFR in ESWL group declined slower after stone removal 
than before undergoing ESWL, although annual eGFR 
changes before ESWL were comparable to those of nephro-
lithiasis patients in the Non-ESWL group. In addition, eGFR 
declined faster after undergoing ESWL in the failure group 
than in the success group. These results suggest that stone 
removal by ESWL is associated with delayed CKD progres-
sion in these patients. The mechanism behind this finding is 
unclear, but removal of kidney stones may improve urine 
flow and decrease repeated short-lived bouts of subclinical 
partial obstructive nephropathy caused by nephrolithiasis. 
Our findings also provide evidence that nephrolithiasis might 
be a risk factor for CKD progression because stone removal 
attenuated kidney function deterioration.
One might argue that acute renal parenchymal injury fol-
lowing ESWL was underestimated in this study. Due to the 
retrospective nature of our study and small number of pa-
tients who underwent ESWL, we could not assess the short-
term effect of ESWL on CKD patients. However, there is a 
possibility that acute kidney injury caused by ESWL is large-
ly reversible without leaving long-term adverse effects, un-
less major complications occur. While previous studies 
showed short-term decline of renal function after ESWL, no 
single study revealed long-term decline of renal function in 
patients without major ESWL complications. Moreover, it is 
unclear whether harmful effects of ESWL on renal function 
would outweigh positive effects from stone clearance by 
ESWL in the long term. In our study, most patients who un-
derwent ESWL did not experience major ESWL complica-
tions. Although hematoma occurred in 2.9% of patients who 
received ESWL, it disappeared in time. In addition, although 
clinically significant urinary tract obstruction from stone 
fragments followed ESWL in 5.8% of patients, it was even-
change, -1.01±4.7 vs. -0.05±5.2 mL/min/1.73 m2/year, 
p<0.05).
DISCUSSION
In this retrospective study on 131 CKD patients with neph-
rolithiasis from a single center, we found that eGFR de-
clined slower in patients who underwent ESWL than in pa-
tients who did not receive ESWL. In addition, we also found 
that eGFR declined faster after undergoing ESWL in the 
failure group than in the success group. Taken together, this 
study suggests that stone removal by ESWL is associated 
with delayed deterioration of renal function in CKD patients 
with nephrolithiasis, implying kidney stones per se might be 
associated with worsening kidney function in CKD patients.
In CKD patients, the rate of GFR decline is generally, 
known to be influenced by several non-modifiable risk fac-
tors such as type of kidney disease, race, baseline GFR, 
gender, and age.11 Besides these non-modifiable risk fac-
tors, a few modifiable patient characteristics such as pro-
teinuria, serum albumin concentration, and blood pressure 
are known to be potent predictors of CKD progression.11 
However, it is totally unexplored to date whether the pres-
ence of kidney stone modifies renal function decline rate in 
patients who already have CKD although many studies re-
ported that kidney stones are associated with CKD, devel-
opment.7-10 To answer this question, we sought to compare 
annual eGFR changes in the same patient before and after 
stone removal. In cases of accompanying hydronephrosis, 
patients’ intrinsic GFR before stone removal may be ob-
scured by coexisting obstructive uropathy, and the effect of 
kidney stones per se on GFR decline rate may not properly 
be evaluated in these patients. Therefore, we excluded neph-
rolithiasis patients with hydronephrosis or staghorn stones.
ESWL is one of the most widely used non-invasive treat-
ment modality for uncomplicated small stones (<2.5 cm) in 
the kidney and upper urinary tract.12 However, it is current-
ly unknown whether stone removal by ESWL improves 
long-term renal outcomes in CKD patients. Therefore, we 
traced eGFR changes before and after stone removal, espe-
cially among patients who underwent ESWL. Several earli-
er experimental animal studies argued against the efficacy 
of ESWL because it induces renal parenchymal injury, pro-
moting further kidney function deterioration.13 Specifically, 
it induces dramatic vascular insult in which capillaries, veins 
and medium-to-small-diameter arteries are torn, accompa-Dong Eun Yoo, et al.
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tually resolved after ureteroscopic procedures. Moreover, 
even urinary tract infections that occurred in 8.7% of pa-
tients after ESWL were all successfully cured with antibiot-
ics therapy. Therefore, it can be surmised that short-term 
harmful effects of ESWL waned over time, while long-term 
positive effect from stone clearance persisted. However, 
this hypothesis needs further investigation.
This study has several limitations. First, as a retrospective 
single-center study, it is subject to the biases inherent to this 
study design. Second, eGFR was used instead of measured 
GFR. Currently, measured GFR using iothalamate is con-
sidered to be the most accurate GFR. However, it is not 
usually used in most of institutes because it is cumbersome 
and inconvenient, and information on iothalamate-GFR 
was not available. Since previous studies revealed that cre-
atinine-based eGFR correlates well with iothalamate-GFR, 
we used MDRD equation to calculate eGFR. Third, exact 
information about kidney stone components was not avail-
able because many stones were not analyzed and few pa-
tients underwent 24-hour urine chemistry tests. However, 
meticulous review of the radiologic examinations of stones 
revealed that no radiolucent stones were included in this 
study. Therefore, most patients in our study likely had calci-
um-based stones. 
In conclusion, our study shows that stone removal by 
ESWL is associated with delayed deterioration of renal 
function in CKD patients with nephrolithiasis. Therefore, 
our findings suggest that ESWL for stone removal should be 
encouraged to prevent further worsening of kidney function 
in these patients. A prospective well-designed study with 
larger study sample is warranted to confirm our findings.
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